A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

Also called NCT05680155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 211 participants (enrolled count) (from the registry)
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd. (from the registry)
Registry
  • NCT NCT05680155
Other papers using this trial's data
  • Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial Nature communications, 2026-01-07 DOI, PubMed 41501026, PMC12881390 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05680155. Randomized; double masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-06-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
Condition
T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ecnoglutide
Intervention (Drug)
Placebo
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05680155
Content hash
a9dc39cc6e035b70b2c0df7255156706e141c22e3494aa50fb25dd85ae7cc564